title: The pathobiology and treatment of Hodgkin lymphoma. Where do we go from Gianni Bonadonna's lesson?
abstract: This article reviews the evolution of the diagnosis and treatment of Hodgkin lymphoma (HL) since its discovery in 1832. The morphological, phenotypic and molecular characteristics of both nodular lymphocyte-predominant HL and classical HL are revised in the light of recent molecular information and possible impact on the identification of risk groups as well as the use of targeted therapies. The seminal contribution of Gianni Bonadonna to developing new treatment strategies for both advanced and early-stage HL is highlighted.
authors.affiliation: Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy.
authors.forename: Simonetta
authors.initials: S
authors.lastname: Viviani
authors.affiliation: Unit of Hematopathology, European Institute of Oncology, Milan - Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Tabanelli
authors.affiliation: Unit of Hematopathology, European Institute of Oncology, Milan - Italy.|Bologna University School of Medicine, Bologna - Italy.
authors.forename: Stefano A
authors.initials: SA
authors.lastname: Pileri
mesh_terms: D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*